Abstracts for annual meeting of the AUA now on line

Readers interested in looking through the 2,600 or so abstracts of papers to be presented at the upcoming annual meeting of the American Urological Association (AUA) can now do so. … READ MORE …

“Angelina Jolie Pitt: Diary of a Surgery”

Whether one agrees with Ms. Angelina Jolie Pitt’s decisions about preventive surgery or not (and some will argue that her decisions are controversial), there is one thing that is very clear. She has used her celebrity to explain, very publicly, the decisions she has been making as a patient about her risk for cancer and what she is doing about that risk. … READ MORE …

The recent “hiatus” in the PCa news

Your sitemaster apologizes for the recent hiatus in new postings to the web site. He was out of the country for several days, without access to the Internet. Hopefully by about Monday he will have been able to “catch up” on any really important news and be back on track. At least he has been able to deal with the outstanding 400+ emails in his inboxes!

Nothing to do with prostate cancer … but the temptation was too strong …

As most readers of this blog will be aware, there are things that men worry about even more than their risk for prostate cancer. So … here is some information from a study just published on-line in BJU International that (for some strange reason) has already been widely picked up by the media. … READ MORE …

Court clears acquisition of Dendreon by Valeant

After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.

Valeant to acquire assets of Dendreon

According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …


Get every new post delivered to your Inbox.

Join 1,261 other followers